Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Mezigdomide?
Mezigdomide is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Relapsed Multiple Myeloma;Refractory Multiple...
Data Insights
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Mezigdomide?
Mezigdomide is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Refractory Multiple Myeloma. According...